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1. INTRODUCTION {#mgg31273-sec-0005}
===============

Central retinal vein occlusion (CRVO) is a common cause of severe vision impairment affecting 1 in 1,000 people in the U.S. (Klein, Klein, Moss, & Meuer, [2000](#mgg31273-bib-0010){ref-type="ref"}). While its prevalence is correlated with advanced age, with the highest risk after the age of 60, recent studies indicate that angiographic findings consistent with CRVO are also observed in younger patients (Blair & Czyz, [2019](#mgg31273-bib-0002){ref-type="ref"}; Recchia, Carvalho‐Recchia, & Hassan, [2004](#mgg31273-bib-0020){ref-type="ref"}). On fundoscopic examination, CRVO is characterized by optic disc edema, diffuse nerve fiber layer thickening, intraretinal hemorrhage, and cotton wool spots (Alasil, Lee, Keane, & Sadda, [2009](#mgg31273-bib-0001){ref-type="ref"}). Glaucoma and ocular hypertension are common comorbidities in patients with CRVO compared with the general population (Hayreh, Zimmerman, Beri, & Podhajsky, [2004](#mgg31273-bib-0008){ref-type="ref"}). CRVO is classified into two distinct categories: nonischemic and ischemic CRVOs. Nonischemic CRVO accounts for about 70% of cases accompanied by good visual acuity (Blair & Czyz, [2019](#mgg31273-bib-0002){ref-type="ref"}). Unlike the milder nonischemic CRVO, ischemic CRVO often accompanies much poorer visual prognosis and generates secondary neovascular glaucoma, which can, in extreme circumstances, lead to enucleation of the eye (Lahey, Kearney, & Tunc, [2003](#mgg31273-bib-0011){ref-type="ref"}).

Patients who experience CRVO are typically found to be in a hypercoagulable state due to an imbalance between anticoagulation and thrombosis in the blood. This hypercoagulable state may not only predispose them to recurrent episodes of retinal vein occlusions but also systemic ischemic events, such as stroke. Two common risk factors for a hypercoagulable state are hyperhomocysteinemia and protein S deficiency. The main cause of hyperhomocysteinemia is a dysfunction of key enzymes of homocysteine biosynthesis (Kim, Kim, Roh, & Kwon, [2018](#mgg31273-bib-0009){ref-type="ref"}), such as methylenetetrahydrofolate (MTHFR) enzyme. The most commonly reported polymorphism of this enzyme is the *MTHFR* (OMIM\# 607093) C677T variant, which is associated with an increased susceptibility to primary open‐angle glaucoma, coronary artery disease, neural tube defects, psychiatric diseases, and pregnancy complications (Lewis, Zammit, Gunnell, & Smith, [2005](#mgg31273-bib-0012){ref-type="ref"}; Moll & Varga, [2015](#mgg31273-bib-0017){ref-type="ref"}). This polymorphism leads to the synthesis of a thermolabile form of the enzyme (Frosst et al., [1995](#mgg31273-bib-0007){ref-type="ref"}), which limits the remethylation cycle of homocysteine metabolism by diminishing the production of the methyl donor, methyltetrahydrofolate. The resulting hyperhomocysteinemia can be controlled by promoting the transulfuration cycle of homocysteine metabolism with sufficient supplementation of vitamin B6 (Liew & Gupta, [2015](#mgg31273-bib-0013){ref-type="ref"}; Maron & Loscalzo, [2009](#mgg31273-bib-0014){ref-type="ref"}). Protein S is a vitamin K‐dependent single‐chain glycoprotein that modulates the coagulation cascade by inhibiting factors Va and VIIIa through the activation of protein C (Miyoshi et al., [2019](#mgg31273-bib-0015){ref-type="ref"}). Reduced activity of protein S is associated with recurrent deep vein thrombosis, pulmonary embolism, nephrotic syndrome, and pregnancy complications (ten Kate & van der Meer, [2008](#mgg31273-bib-0022){ref-type="ref"}; Vigano‐D\'Angelo et al., [1987](#mgg31273-bib-0023){ref-type="ref"}).

The *MTHFR* C677T variant and protein S deficiency give rise to a high level of plasma homocysteine and disruption of the coagulation cascade, respectively. Strikingly, both conditions have been associated with venous thrombosis in the literature, but the exact pathophysiologic mechanism remains unclear (D\'Angelo & Vigano D\'Angelo, [2008](#mgg31273-bib-0004){ref-type="ref"}; den Heijer et al., [1996](#mgg31273-bib-0005){ref-type="ref"}; Lahey et al., [2003](#mgg31273-bib-0011){ref-type="ref"}).

Hereby, we present a rare case of CRVO followed by a transient ischemic attack in a 51‐year‐old Asian woman secondary to both the homozygous *MTHFR* C677T variant and protein S deficiency. Close monitoring of patients with these conditions, as well as their family members, is imperative, as the history of CRVO can predict other impending thromboembolic episodes.

2. METHODS {#mgg31273-sec-0006}
==========

Eight years of continuous follow‐up was performed of one patient diagnosed with CRVO who presented to the Applied Genetics Clinic at Edward S. Harkness Eye Institute, Columbia University Irving Medical Center. The study followed the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board (Protocol number AAAR8743). Written consent was not required as analysis was performed through retrospective review and there was no more than minimal risk to the patient. No information or image is identifiable to the patient. The patient\'s peripheral blood was used for metabolic evaluation and hypercoagulability assessment. Examination of the retinal vasculature was performed through funduscopic examination, and digital color fundus and ultrawide‐field color fundus photography (Optos, Dumfermline, UK). Spectral domain optical coherence tomography (SD‐OCT) images and fluorescein angiography were acquired using a confocal scanning laser ophthalmoscope (cSLO; Spectralis HRP + OCT, Heidelberg Engineering). Targeted gene sequencing by PCR identified the homozygous *MTHFR* C677T variant.

3. CASE PRESENTATION {#mgg31273-sec-0007}
====================

3.1. Initial presentation {#mgg31273-sec-0008}
-------------------------

A 51‐year‐old woman of Asian descent with an ocular history of branched retinal vein occlusions (BRVO) and a medical history of hyperlipidemia was referred to the Edward S. Harkness Eye Institute at Columbia Irving Medical Center (New York, NY, USA) for reported blurry vision, flashes, and floaters. Prior to her initial visit, she experienced one episode of BRVO in her right eye 1 year prior and two episodes of CRVO 20 years and 7 years prior. She had a prior optic neurotomy performed in the left eye.

Targeted genetic sequencing by PCR revealed a homozygous C677T polymorphism in the *MTHFR* gene which was consistent with the patient\'s history of central and branched retinal vein occlusions. The metabolic profile (Table [1](#mgg31273-tbl-0001){ref-type="table"}) from the peripheral blood indicated low protein S activity, high levels of vitamin B6, LDL cholesterol, and free antigen against protein S while normal homocysteine level, likely due to vitamin B6 supplementation.

###### 

Metabolic evaluation and hypercoagulability assessment at first visit

  Test                                              Patient results        Reference range
  ------------------------------------------------- ---------------------- -----------------------------------------------
  Prothrombin time (s), INR                         12.1, 1.0              10.3--14.1, \<1.5
  Activated partial thromboplastin time (s)         34.7                   28.9--38.1
  Antiphosphatidylserine IgG (phospholipid units)   0                      ≤16
  Antiphosphatidylserine IgM (phospholipid units)   4                      ≤22
  Anticardiolipin IgG (phospholipid units)          6                      \<23
  Anticardiolipin IgM (phospholipid units)          3                      \<11
  Anticardiolipin IgA (phospholipid units)          5                      \<22
  Antithrombin III activity (Xa based) (%)          80                     80--120
  Protein C activity (%)                            153                    74--172
  Protein S activity (%)                            42                     62--136
  Protein S antigen, free (%)                       134                    65--125
  *MTHFR* C677T polymorphism                        Positive, homozygous   Negative
  *Factor V Leiden* polymorphism                    Negative               Negative
  *Prothrombin* polymorphism                        Negative               Negative
  Homocysteine (μmol/L)                             11.36                  3.7--13.9
  Folate (ng/ml)                                    \>20                   ≤4.8
  Vitamin B6 (nmol/L)                               308                    20--125
  LDL cholesterol (mg/dl)                           105                    \<100
  Plasma glucose (mg/dl)                            112                    65--139
  HgA1c (%)                                         6.1                    \<7[^a^](#mgg31273-note-0002){ref-type="fn"}
  Plasma creatinine (mg/dl)                         0.7                    0.5--0.99
  BUN (mg/dl)                                       10                     7--25
  BUN/ creatine ratio                               Normal                 Normal
  GFR (ml min^−1^ 1.73 m^−2^)                       \>60                   \>60[^b^](#mgg31273-note-0003){ref-type="fn"}

Normal value for patients diagnosed with diabetes, as reported by the laboratory.

Normal value for patients of race respective to that of the patient.

John Wiley & Sons, Ltd

Ophthalmic history was significant for multiple CRVOs and optic nerve neurotomy in the left eye performed previously (Figures [2](#mgg31273-fig-0002){ref-type="fig"} and [3](#mgg31273-fig-0003){ref-type="fig"}). At the initial visit, the patient\'s best‐corrected visual acuity was 20/20 in the right eye and 20/60 in the left. Fundus angiography revealed a hypoautofluorescent punctate blocking defect in the superior temporal arcades of the right eye (Figure [1](#mgg31273-fig-0001){ref-type="fig"}) along with a hyperfluorescent window defect at the temporal periphery. Notably, the left eye demonstrated hyperfluorescent staining of the radial neurotomy scar nasal to the optic disk (Figure [1](#mgg31273-fig-0001){ref-type="fig"}).

![Fluorescein Angiography at the Initial and Most Recent Visits. Fluorescein angiography of the right eye at the initial visit demonstrates the presence of a hypofluorescent punctate blocking defects in the superior temporal arcade along with hyperfluorescent window defect at the temporal periphery. On follow‐up examination, the blocking defects resolved but the window defect persisted. Moreover, hyperfluorescent staining of microaneurysms in the superior and inferior temporal arcades was seen. On the left eye, the angiography demonstrated a hyperfluorescent staining of the radial neurotomy scar at the nasal border of the optic disk. Hyperfluorescent aneurysms can be appreciated at the temporal arcades at both visits](MGG3-8-e1273-g001){#mgg31273-fig-0001}

3.2. Progression {#mgg31273-sec-0009}
----------------

One year after the patient\'s initial visit, she endorsed a subjective decrease in color and near vision despite stable retinal examination. The following year, she experienced a transient ischemic attack, resulting in a left‐sided weakness of the arm and gait impairment, which resolved with aspirin. Seven years after the initial visit, the patient\'s retinal veins were appreciated to have increased in diameter and the arterioles narrowed based on ophthalmic examination.

3.3. Recent visit {#mgg31273-sec-0010}
-----------------

The following year, the patient was diagnosed with two new microaneurysms in the right eye and one in the left eye. At the most recent visit, the patient\'s best‐corrected visual acuity was 20/30 in the right eye and 20/40 in the left. Follow‐up fundus angiography of the right eye revealed that previously observed blocking defects had resolved and the hyperfluorescent window defect persisted. Moreover, hyperfluorescent staining of microaneurysms in the superior parafoveal arcade was present. On the other hand, the left eye progressed with hyperfluorescent staining secondary to microaneurysms in the inferior temporal arcade in addition to an area of nonperfusion at the inferior temporal periphery of the retina. Color fundus photography at this visit revealed multiple microaneurysms located along the superior arcades of the right eye as well as one microaneurysm along the arcades of the inferior retinal vein and at the superior retinal vasculature in the left eye (Figures [2](#mgg31273-fig-0002){ref-type="fig"} and [3](#mgg31273-fig-0003){ref-type="fig"}). No signs of neovascularization, leakage, or vein occlusion were observed.

![Optical Coherence Tomography at the Initial and Most Recent Visit. Optical coherence tomography demonstrates the presence of an epiretinal membrane in the right eye at the initial visit that had resolved at the recent examination (a & c). Hyperreflective dot was seen in the right parafovea at initial visit with complete resolution at follow‐up (a & c). Granular interruption of the ellipsoid zone line can be appreciated at the fovea in both eyes at initial visit that has since resolved (a--d). Furthermore, retinal thinning due to inner layers atrophy was seen in both eyes in addition to an atrophy of the outer nuclear layer in the left eye (a--d)](MGG3-8-e1273-g002){#mgg31273-fig-0002}

![Color Fundus Photography at the Initial and Most Recent Visit. Color fundus photography at the initial visit demonstrates the presence of small microaneurysms found at the tip of the temporal arcades of the right eye (a). Radial optic neurotomy scar can be appreciated at the nasal aspect of the optic disc in the left eye (b). At a recent visit, an increased number of microaneurysms can be appreciated along the superior arcades of the right eye as well as one along the arcades of the inferior retinal vein (c). Microaneurysms can be appreciated along the superior and inferior retinal vasculature of the left ey](MGG3-8-e1273-g003){#mgg31273-fig-0003}

4. RESULTS {#mgg31273-sec-0011}
==========

Metabolic assessment at the initial visit showed abnormalities in protein S activity, free protein S antigen, serum folate, Vitamin B~6~, and LDL levels (Table [1](#mgg31273-tbl-0001){ref-type="table"}). A hypercoagulability assessment identified a polymorphism in the *MTHFR* (C677T) gene. The patient\'s plasma homocysteine was controlled prior to her initial visit with supplementation of vitamin B6 (Table [1](#mgg31273-tbl-0001){ref-type="table"}). However, the patient reported noncompliance with her anticoagulant therapy, mainly due to the inconvenience of the periodic injections. Low‐dose aspirin and atorvastatin for hypercholesterolemia were added to her medication regimen. Metabolic evaluation at recent visits showed consistently controlled levels of homocysteine (7.5 and 7.6 µmol/L) (Table [2](#mgg31273-tbl-0002){ref-type="table"}).

###### 

Levels of homocysteine, vitamin B12, and folate over time

  Test                    Patient results   Reference range          
  ----------------------- ----------------- ----------------- ------ --------------
  Homocysteine (µmol/L)   11.36             7.5               7.6    3.7--13.9
  Vitamin B12 (pg/ml)     N/A               1522              530    200--1100
  Folate (ng/ml)          \>20              \>20              \>20   [\>]{.ul}4.8

The values reported for the year 2009 reflect the patient\'s results at the initial visit.

Abbreviation: N/A = not available.

John Wiley & Sons, Ltd

5. DISCUSSION {#mgg31273-sec-0012}
=============

This case report illustrates a rare case of CRVO followed by a systemic ischemic episode in a patient with a simultaneous presentation of the homozygous *MTHFR* C677T variant and protein S deficiency. It demonstrates the potential for an ocular condition to serve as a principal indicator of the development of a systemic impairment. We propose that the reduced functions of MTHFR and protein S deficiency triggered the interplay between two components of Virchow\'s Triad---hypercoagulability and endothelial damage---in the development of CRVO. Homocysteine inhibits the synthesis of nitric oxide, an antiatherogenic substance, an absence of which indicates vascular disease and mortality (Stuhlinger et al., [2001](#mgg31273-bib-0021){ref-type="ref"}). Although the pathophysiology is controversial, hyperhomocysteinemia is also strongly associated with endothelial damage, which exposes the subendothelial matrix and initiates thrombus activation (Vine, [2000](#mgg31273-bib-0024){ref-type="ref"}).

Consistently, prior studies have identified hyperhomocysteinemia as a risk factor for recurrent venous thrombosis, with women at a higher risk (OR 7.0, 95% CI 1.6--30.8) than men (OR 1.4, 95% CI 0.6--3.4) across all ages (den Heijer et al., [1996](#mgg31273-bib-0005){ref-type="ref"}). In our patient, serum hypercoagulability coupled with endothelial damage resulted from the *MTHFR* polymorphism and protein S deficiency contributed to the development of the transient ischemic attack 2 years postdiagnosis. In addition to the *MTHFR* variant and protein S deficiency, medical history of hypertension, diabetes, and hyperlipidemia also increased the patient\'s susceptibility to thrombosis (Previtali, Bucciarelli, Passamonti, & Martinelli, [2011](#mgg31273-bib-0019){ref-type="ref"}).

The narrowing of both the retinal vein and artery noted on fundoscopic examination at 6 years posttransient ischemic attack represented significant risk factors for future retinal occlusions (Newman, Andrew, & Casson, [2018](#mgg31273-bib-0018){ref-type="ref"}). These findings suggest an etiology for the development of the microaneurysms in the right and left eyes in the following year. Furthermore, they indicate an impending venous occlusion and a high possibility of aneurysms or leakage elsewhere in the body, such as vein thrombosis, pulmonary embolism, acute coronary syndrome, or myocardial infarction (Liew & Gupta, [2015](#mgg31273-bib-0013){ref-type="ref"}).

The precise pathogenesis of CRVO is yet to be established but is expected to be multifactorial (Cugati et al., [2007](#mgg31273-bib-0003){ref-type="ref"}). We suggest that the reduced activity of MTHFR and protein S in combination with patient\'s medical conditions likely caused a synergistic development of the hypercoagulable state. Radial optic neurotomy, which the patient received to relieve the tension in the optic nerve head, is one of the treatment options for patients with CRVO. However, its biomedical effect on ameliorating the signs of CRVO has been reported as negligible (Friberg, Smolinski, Hill, & Kurup, [2008](#mgg31273-bib-0006){ref-type="ref"}). While other options include intravitreal triamcinolone, anti‐VEGF agents, chorioretinal anastomoses, and vitrectomy (Mohamed, McIntosh, Saw, & Wong, [2007](#mgg31273-bib-0016){ref-type="ref"}), there has not been an ample number of randomized controlled trials to evaluate their safety and efficacy. Retinal vein occlusion is correlated with higher risk of cardiovascular and cerebrovascular mortality for all ages (Cugati et al., [2007](#mgg31273-bib-0003){ref-type="ref"}). Therefore, retinal occlusions warrant special attention for signaling the possible development of subsequent thromboembolic episodes in other body vasculature and consequently the need to initiate aggressive preventative therapeutic measures.
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